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Abstract
Background: Patient and public involvement (PPI) in studies carried out by the UK Medical Research Council Clinical
Trials Unit (MRC CTU) at University College London varies by research type and setting. We developed a series of case
studies of PPI to document and share good practice.
Methods: We used purposive sampling to identify studies representing the scope of research at the MRC CTU and
different approaches to PPI. We carried out semi-structured interviews with staff and patient representatives. Interview
notes were analysed descriptively to categorise the main aims and motivations for involvement; activities undertaken;
their impact on the studies and lessons learned.
Results: We conducted 19 interviews about ten case studies, comprising one systematic review, one observational
study and 8 randomised controlled trials in HIV and cancer. Studies were either open or completed, with start dates
between 2003 and 2011. Interviews took place between March and November 2014 and were updated in summer
2015 where there had been significant developments in the study (i.e. if the study had presented results subsequent to
the interview taking place). A wide range of PPI models, including representation on trial committees or management
groups, community engagement, one-off task-focused activities, patient research partners and participant involvement
had been used. Overall, interviewees felt that PPI had a positive impact, leading to improvements, for example in the
research question; study design; communication with potential participants; study recruitment; confidence to carry out
or complete a study; interpretation and communication of results; and influence on future research.
Conclusions: A range of models of PPI can benefit clinical studies. Researchers should consider different approaches to
PPI, based on the desired impact and the people they want to involve. Use of multiple models may increase the
potential impacts of PPI in clinical research.
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Background
Patient and public involvement (PPI) in research describes
a variety of activities ensuring that research is carried out
in collaboration with patients and/or members of the pub-
lic [http://www.invo.org.uk/find-out-more/what-is-public-
involvement-in-research/]. There are a number of argu-
ments to support PPI. In publicly funded research in
particular, these revolve around accountability and
democracy [1]. On a more practical level, many re-
searchers believe that involvement improves the overall
quality of the study and increases the likelihood that a
study will be successful [2–5]. Increasingly, many fund-
ing bodies are encouraging or insisting upon some form
of PPI in the clinical studies they fund.
The MRC Clinical Trials Unit (MRC CTU) at Univer-
sity College London (UCL) designs, conducts, analyses
and reports high-quality randomised controlled trials
(RCTs), meta-analyses and other clinical studies in a var-
iety of health-care areas, primarily cancer, HIV and other
infectious diseases. The unit is committed to active PPI
in all its clinical research and has developed a policy and
accompanying guidance to support this (these documents,
or details of how to obtain them, can be found at
http://www.ctu.mrc.ac.uk/resources/patient_involvement).
This work is overseen by a PPI steering group, which is
currently made up of eight members of staff from each of
the major areas and types of clinical research carried out
by the unit (cancer, HIV treatment and prevention, tuber-
culosis, RCTs, meta-analysis and observational studies),
two patient representatives (one involved in HIV research
and one primarily in cancer) and two external PPI experts.
We previously reported the results of a survey explor-
ing PPI in the unit, from the researchers’ perspective [6].
Researchers were asked to describe PPI activities in stud-
ies spanning more than 20 years. Whilst there was little
or no involvement noted in the older studies, the major-
ity of the more recent studies reported some PPI activ-
ities (e.g. patient representation on a formal trial group
or committee). Encouragingly, most of the researchers
who participated in the survey perceived benefits of PPI
in their research.
The PPI steering group became aware that a variety of
different approaches to PPI were being used in newer
studies in the unit. These varied dependent upon study
characteristics including disease, setting, population, geog-
raphy, the stage of the study and the specific aims of the
involvement. The group developed a series of case studies
of PPI with the aim of documenting the models used and
their aims, to gain a better understanding of PPI across
different types of research being conducted within the
unit. Furthermore, we aimed to highlight innovative PPI
for future research and share examples of good practice.
Much of the literature of PPI in clinical trials is reports
of single case studies [7] or surveys with, necessarily, less
detail about the context of individual studies and PPI
approaches used [8]. There have been several publications
that have looked systematically at PPI in a cohort of trials
covering a range of diseases [9–11]; however, these have
been limited to trials taking place in a single country
(the UK). Here we present the findings from case studies
covering a range of geographical settings, study designs
and patient populations, allowing us to make comparisons.
Methods
The original idea for this work came from a participant at
a workshop for involved patients and patient organisations
hosted at the unit in June 2013 (workshop report available
from: http://www.ctu.mrc.ac.uk/13706/13710/promoting_
patient_and_public_involvement_in_clinical_trials_at_the_
medical_research_council_clinical_trials_unit). We used
purposive sampling to identify a cohort of studies
representing the scope of our research and different ap-
proaches to PPI, and the geographical range of our
studies. Our definition of PPI is based on that of INVOLVE
(http://www.invo.org.uk/find-out-more/what-is-public-in-
volvement-in-research/), and is the active involvement of
patients, carers or family members, health service users,
patient representatives or members of groups or organisa-
tions that represent those affected by the condition being
researched as partners in the research process.
Once we had identified the cohort of studies, the lead re-
searcher (or other key staff member) was invited to partici-
pate in semi-structured interviews around PPI within the
study. We asked the researcher we interviewed from each
study to nominate one or more patient, lay or community
representatives who had been involved in the study to be
interviewed also. None of the patient, lay or community
representatives we interviewed were participants in our co-
hort of studies. We (BH) conducted these face to face
wherever possible (otherwise over the telephone), following
a topic guide designed to capture qualitative information
on who was involved, the aims of involvement, the types of
activities carried out by those involved, the support pro-
vided to those involved, the costs of PPI and its impact on
the studies. It also included questions on motivation for in-
volvement and lessons learned for the future. The full topic
guide is provided in the Appendix.
Application of the National Health Service (NHS) research
ethics committee Health Research Authority decision-
making tool (http://www.hra-decisiontools.org.uk/ethics/)
indicated that because our research was not a clinical trial
of a medicinal product or device, no clinical data were col-
lected and the interviewees were neither identified from
or because of their past or present use of services, ethics
approval was not necessary, and on this basis, was not
sought. The UCL research ethics committee exempts
‘Research involving the use of non-sensitive, completely
anonymous educational tests, survey and interview
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procedures when the participants are not defined as
“vulnerable” and participation will not induce undue
psychological stress or anxiety’ from the requirement to
seek ethical approval from the committee. As our study
met these criteria, as a service evaluation of PPI within
our trials, ethical approval from the UCL research eth-
ics committee was not sought. Interviewees gave verbal
consent to being interviewed, and for the notes of these
interviews to be analysed and published.
The face-to-face interviews took place in meeting rooms
at the office of the unit. The interviews lasted approxi-
mately 45 min. The interviews were not audio-recorded
and transcribed, as this project was initially designed to
gather information for internal use rather than publica-
tion. Written summaries of each interview were produced
instead, as a less time-consuming approach. Inaccuracies
or inconsistencies were resolved with the interviewees,
who also verified the final versions. One author (AS)
then analysed the content of the summaries, following
a process of familiarisation with the data, creating tables
with data extracted from the written summaries organised
by topic (based on the interview guide) to allow for com-
parison across the case studies, and identifying initial
themes. The tables and initial themes were shared with
the MRC CTU PPI steering group, who discussed and
agreed the themes (BH, BC, RS, KSc, CV and AS). The
group also discussed and agreed the final interpretation
(BH, BC, RS, KSc, CV, AS, KSt, WJC, CDT, JT and MG).
Responses from research staff and PPI contributors were
considered separately where possible and appropriate.
Results
The unit currently has around 50 active clinical studies
(predominantly RCTs). We identified 11 studies (nine
RCTs, one observational study and one meta-analysis)
that we wanted to do case studies on to represent the di-
versity of types of clinical studies (design, geographical
setting, disease and patient population) and approaches
to PPI within the unit. We approached the lead researcher
at the unit for each of these, of whom ten out of 11 agreed
for a case study to be done on the PPI within their study.
The reason given for not agreeing was that the researcher
felt that there had not been much PPI in their study.
We interviewed all patient representatives who the lead
researcher identified and put us in touch with. We con-
ducted 19 interviews with 13 researchers and seven patient
representatives (one interview included two researchers
from the same study), collecting information on eight
individual RCTs [12–19] and one observational study
[20], covering either cancer or HIV. The interviews
took place between January and November 2014. In
addition, data that had been collected for a previous pro-
ject from two researchers and four patient representatives
regarding PPI in a meta-analysis [21] were included for
completeness, and provided the data for the analysis.
Most of the patient representatives interviewed were
directly affected by the condition being studied in the
trial, while one had been a carer for someone with the
condition and two were employed by patient groups.
The studies included six that were primarily carried out
in the UK, two in sub-Saharan Africa and two across
multiple continents. Table 1 gives an overview of the
studies included and the full interview summaries are
available upon request. The full interview notes can be
found in Additional file 1.
The main approach to recruiting patient and community
representatives was via patient groups or by approaching
people who were already involved in other research (for
example, through the National Cancer Research Institute
(NCRI) Consumer Liaison Group (CLG)). Three studies
[12, 13, 16] involved study participants (in addition to
patient or community representatives who were not
taking part in the study) directly and tended to do so
through advertisements in clinics and/or the study web-
site and participant mailing list. For most of the case
studies, little specific information was reported about
the additional costs associated with PPI, so we do not
present those findings here.
We categorised the findings into aims and motivations
for PPI, models of involvement, impacts of involvement
and lessons learnt. These findings are presented below.
Aims and motivation for PPI
We found that the trial teams broadly agreed on their
reasons for involvement. All researchers interviewed said
that PPI gave them the opportunity to understand better
the perspectives of the affected population. Some of the
researchers interviewed were more specific, saying that
PPI had provided help with issues around recruitment
and/or retention, and, in the case of the two HIV preven-
tion trials, to ensure acceptability of the study. Two trials
also mentioned that PPI was a condition of their Health
Technology Assessment (HTA) funding.
There were also considerable similarities in the motiva-
tions patient representatives cited for being involved in
the studies; for example, wanting to help with research
that they felt was addressing an important question
(8/11 patient representatives). While being affected by
the condition (or caring for someone who was) was
often a criterion for becoming a patient representative
on these studies, it was not explicitly cited by the patient
representatives as a motivating factor. Other reasons
mentioned included interest in research, a desire to
learn more about clinical trials, a desire to put forward
a patient’s perspective, and a feeling that they had the
time and skills needed to contribute.
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Models of involvement
In this section we describe the models of involvement in
terms of who was involved in the PPI, the types of activ-
ities included and the support offered. Table 2 summarises
the main models of involvement used in the study.
The most common models of PPI were having patient
or community representatives on either the trial steering
committee (five studies) or the trial management group
(three studies), reflecting the typical management struc-
tures of the cancer and HIV trials within the unit. HIV tri-
als (AALPHI [20], BREATHER [17], DART [12], PIVOT
[18] and PROUD [16]) commonly involved community
members or patients on the study’s steering committee, a
high-level group that oversees the conduct of the study.
For the cancer trials (QUARTZ [14], SORCE [19] and
STAMPEDE [15]), involvement was on the trial manage-
ment groups, which are responsible for the set-up and
day-to-day running of the trial and release of results or
publications. Several patient or community representatives
who were involved in these types of formal trial commit-
tees were people who already had experience of PPI activ-
ities, or were active in patient groups or organisations.
They tended to have a good understanding of research
processes and/or the disease area and had established
links with the patient community. Two HIV studies had
patient or community representatives on the data mon-
itoring committee. Where studies involved patients or
community representatives on formal committees, they
tended to involve one or two representatives per com-
mittee (although the individuals may change over the
course of the study). Two studies (QUARTZ and SORCE)
involved only one representative in total. In general, meet-
ings between researchers and patient or community
representatives were held either face to face or by tele-
phone. Payment and provision of support for patient
and community representatives were mixed such that
for some studies, there was no budget to enable payments
to be made, but for the cancer trials (QUARTZ [14],
SORCE [19] and STAMPEDE [15]) and the AALPHI
study [20], the representatives’ expenses were covered and
a fee was paid. Although most of the patient and commu-
nity representatives received no formal training, most said
that they were offered background information at the start
of the study and also talked about how MRC CTU staff
and/or other committee members had been helpful when
they had questions.
In addition to representation on trial oversight or man-
agement groups, the HIV studies each employed other
models of involvement. For example, patients and com-
munity members were involved in peer support groups,
participant meetings or community engagement groups,
some of which had formal membership and regular meet-
ings, while others were ad hoc. We do not have data on
how many patient and community representatives were
involved in these more responsive roles for each of the
case studies that used these approaches, although it was
likely to be 5–20 per task for AALPHI and BREATHER,
with many more than that involved over the course of
MDP301 and PROUD. They involved a broad spectrum
of people, many of whom would have had no previous
involvement or experience. Some studies worked with
community organisations to facilitate involvement, in
particular, the studies involving young people affected
by HIV. For example, in the AALPHI study [20], commu-
nity groups worked with young people to test interviews,
improve the design of study materials and develop a
video explaining the study to potential participants. In
the BREATHER trial [17], the Children’s HIV Association
facilitated a meeting with researchers, children and young
people to discuss the study and to define topics for the
qualitative interviews.
The single meta-analysis [22] involved five women, each
of whom had experienced cervical cancer, as a group of
research partners. Their role included helping to trace
contact details for trial investigators, contributing to
project newsletters, helping with the organisation of a
collaborators’ meeting, providing input to the lay summary
and a key messages document, and taking part in discus-
sions about future research.
Impacts of PPI
All interviewees felt that PPI had impacted on the study,
although the type of influence varied. Overall, the impacts
were categorised into seven of the nine key areas of im-
pact outlined in the public involvement impact assessment
framework (PiiAF, http://piiaf.org.uk/). In our case studies,
we had no examples of PPI impact on data collection
or time and cost. Table 1 includes the areas of impact
reported in each of the case studies.
Influence on research design and delivery
Six of the studies reported that PPI had a positive influ-
ence on the research question and/or design of the study.
For example, in the QUARTZ trial [14], researchers antici-
pated that there may have been problems collecting qual-
ity of life data from patients, as they had very advanced
stages of lung cancer and may have been too unwell to re-
spond. However, in response to a suggestion from the PPI
representative on the trial management group, the final
study design included collection of responses from carers,
as a proxy for the patients. In the MDP301 trial [13], po-
tential participants voiced their concerns about the ability
of clinics to sterilise the instruments being used in the
clinics at community engagement meetings, resulting in
the use of disposable instruments in the trial. In the
PROUD study [16], the community engagement group
had concerns that the use of a placebo control might ham-
per recruitment. They advocated instead for the use of a
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deferred control arm and also for a simple, daily dosing
schedule, thus directly influencing the design of the study.
Finally, a patient representative on the PIVOT trial
steering committee raised concerns that recruitment to
a sub-study of the trial may be problematic, as the study
involved patients having a lumbar puncture. As a result,
the sub-study was redesigned and the target number of
participants was reduced substantially.
Impact on ethics and recruitment
The PiiAF framework classes are ‘improving the consent
process by producing clearer more accessible information’
under the heading of ‘ethics’. We believe that improvements
in communication with potential participants can have (and
in some of our studies, have had) an impact on recruitment
to the study. Therefore, we look at these two areas of the
PiiAF framework together. Eight studies reported improved
communication with potential participants and/or impacts
on recruitment as a benefit of PPI. For example, the patient
representative on the QUARTZ trial management group
gave talks about the trial at meetings that led to new clini-
cians signing up to the trial. Patient representatives on the
SORCE and STAMPEDE trial management groups identi-
fied the need for clearer and simpler patient information
sheets. Young people worked with a community organisa-
tion to design a logo and posters to promote the AALPHI
study [20] and produced a short video to explain the study
in a way that is fun and understandable.
In MDP301 [13], regular meetings with participants
through the duration of the trial informed recruitment and
retention and communications and dissemination strat-
egies. They also helped to hone the trial messages. In
addition, the community advisory board and participant
stakeholder group worked with the research team to pro-
vide a swift and appropriate response to community con-
cerns about the closure of another microbicide study. This
helped to avoid any potential negative impact on the
MDP301 study. Researchers on the DART trial [12] also felt
that community involvement was a key contributing factor
to the very high levels of recruitment and retention in the
trial, through creation of a sense of a DARTcommunity.
HIV trials in the UK often struggle to recruit partici-
pants of African origin. The PIVOT team [18] worked
with the African Eye Trust to address this. Trust mem-
bers gave presentations about the trial at a number of
hospitals and clinics, and included an article about the
trial in their magazine. More than 20 % of PIVOT par-
ticipants were of African origin, which is a much higher
proportion than for many other UK HIV studies.
Giving researchers the confidence to do or continue a study
Trials do not always go smoothly; for example, recruit-
ment may be slower than anticipated and researchers then
have to make the difficult decision on whether to continue
the trial. In the case studies, researchers, including from
the QUARTZ [14] and PROUD trials [16], reported that
PPI had given them the confidence to keep going with a
study when recruitment was slower than anticipated. The
researchers also reported that patient or community rep-
resentatives had reassured them of the importance of the
trial.
Researchers on the STAMPEDE trial [15] highlighted
the important role that two patient representatives on
the trial management group had played prior to the trial
opening. A drug similar to one of those due to be inves-
tigated in STAMPEDE was withdrawn from the market
due to safety concerns and all trials involving this family
of drugs were stopped indefinitely. The STAMPEDE trial
management group had to decide whether to drop this
drug from the trial or to wait until there was further
guidance from the regulatory authorities. The patient rep-
resentatives played a key role in assessing the potential
risks and benefits of the drug for men with prostate can-
cer, and in the decision to wait rather than going ahead
without it.
In PIVOT [18], the patient representative on the data
monitoring committee persuaded the committee to con-
tinue with the study at least until further evidence was
available, following a serious adverse event to a participant
that may or may not have been related to the trial treat-
ment. Having the view of a patient on the balance between
risk and benefit gave the members of the data monitoring
committee more confidence in their decision.
Impact on analysis, writing-up and dissemination
There was considerable overlap in what interviewees re-
ported in terms of the impact on analysis, writing-up
and dissemination, therefore they are discussed together.
Three studies reported that PPI had impacted on the in-
terpretation and communication of the results. For ex-
ample, when preliminary results of a PIVOT sub-study on
cognitive impairment were presented at an investigators’
meeting, the patient representative on the trial steering
committee was concerned about the language used and
the appropriateness of the analysis, which had not taken
socio-economic and cultural factors into account. This led
the researchers to make appropriate adjustments to the
analysis before the results were more widely disseminated.
Similarly, the researchers involved in the PROUD trial
[16] held a number of meetings to gather feedback from
participants on the study results, which led them to
change the emphasis of the key messages prior to their
public release. Initially researchers had planned to empha-
sise in the key messages the high risk of HIV faced by this
group, but following feedback from participants, the em-
phasis was reduced due to a concern about stigmatisation
of the participants.
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Three of the patient research partners on the cervical
cancer meta-analysis [22] wrote a joint article with the
researchers to describe the side effects of cervical cancer
treatment from a patient’s perspective [23], helping to
place the results in the context of patient experience.
Impact on future research agenda
The case studies also highlighted that where there is PPI
in an ongoing or ending study, there is an opportunity
for PPI input into future studies, which often follow on
from existing studies, and may involve many of the same
researchers and patient representatives. For example, the
patient research partners on the cervical cancer meta-
analysis raised concerns about the lack of information
on the late side effects of cervical cancer treatment avail-
able from the meta-analysis. This led to researchers col-
laborating in a separate research project with a greater
focus on late side effects.
Another example is that the patient representative on
the SORCE trial management group became involved in
the trial development group, designing a follow-up study
to SORCE on renal cancer.
As recruitment to the PROUD pilot study came to an
end, participants contributed to discussions about the
future research priorities for HIV prevention among men
who have sex with men in the UK through participant in-
volvement meetings via a webinar and teleconference.
These were advertised through the study website, study
newsletter and in study clinics. Their discussions helped
to directly inform the development of a funding applica-
tion to the HTA programme.
Lessons learnt
Researchers and patient representatives were asked what
advice they would give to researchers looking to involve
patients and the public, and shared their key lessons for
future studies. These can be broadly grouped into three
areas: who to involve, types of involvement and provid-
ing support. Advice on who to involve centred on the
skills, characteristics or background required and on re-
cruitment. Lessons around types of involvement tended
to be reflections of what worked well in the study the
interviewee was involved in. Discussion of support in-
cluded the support that can be given by the research
team, support available from existing community or pa-
tient groups, and the support other patient representa-
tives can provide. Further details are presented in Box 1.
Discussion
In our study, the case studies demonstrate that a range
of models and approaches to PPI have led to numerous
benefits across the key areas of impact, with examples
from the design phase through to interpreting and
communicating the results of studies. Motivations for
involvement, both from the researchers and from the
patient and public representatives who were interviewed
were broadly similar with an overall aim of improving the
study.
These case studies follow on from a survey of PPI in
MRC CTU studies, the results of which we reported pre-
viously [6]. Clearly, they do not provide a complete pic-
ture of all PPI in research carried out by the MRC CTU,
or indeed, more widely. Our aim for this study was to
provide a detailed look at the ten studies chosen, to pro-
vide clear illustrations and examples of PPI across the
range of research activities in the MRC CTU and to evi-
dence the impact of PPI on those studies. Although
there are numerous difficulties in assessing the impact
of PPI in clinical research, we found a variety of impacts
that fit well into the framework of public involvement
impacts on research identified by the PiiAF project
(http://piiaf.org.uk/). These covered each of the areas of
agenda, research design and delivery, ethics, recruitment,
analysis of data, writing-up and dissemination. Like the
case studies evaluated by Evans et al. [24, 25], PPI was
reported to have had some impact in all our studies, par-
ticularly in recruitment and materials. Like the EPIC sur-
vey of HTA-funded trials [25], none of our informants
reported PPI as having had a negative impact on the study.
It should be noted that a number of the case studies
were about research that was still ongoing at the time
of the interviews. Therefore, there are fewer examples of
impact on the latter stages of the research process (ana-
lysis of data, writing-up and dissemination).
There is a growing body of literature around PPI;
however, examination of the INVOLVE Evidence Bibli-
ography reveals that most references that focus on PPI
in clinical trials are case studies of individual trials [7],
limiting generalisability. Our study adds to the existing
literature through providing details of, and comparing
and contrasting PPI undertaken in eight RCTs, encom-
passing different disease areas, geographical locations and
approaches to PPI. The multiple case studies approach al-
lows us to provide more depth than higher-level surveys
across many trials, but as the sample was purposively
selected, it lacks the generalisability of more systematic
approaches, such as the EPIC study [9, 10].
Our analysis of the data is limited by the lack of
audio-recording and verbatim transcriptions of the inter-
views. Relying on written summaries of the interviews
may mean that we have missed key information. However,
we are confident that the written summaries are accurate
and contain the points considered important by inter-
viewees, as all our interviewees were asked to read and
correct or approve the written summaries prior to the
start of analysis.
Our findings have enabled us to describe better the
wide variety of approaches being used to involve patients
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and the public in our research. In keeping with the find-
ings of a previous survey of how consumers were involved
in NHS research [8], most often patient or community
representatives were involved in trial steering committees,
trial management groups and data monitoring commit-
tees. A systematic cohort investigation of HTA-funded tri-
als also found that the most common approach to PPI
was in a managerial role [10]. The representatives tended
to be people who were already active in patient groups or
other PPI activities. This has several advantages, including
knowledge of research and the disease and having links
with other patients. Having less formal approaches to PPI
may offer different advantages. For example, it may help
to involve people who are not comfortable in formal
meetings and those who are unable to make a long-
term commitment, which may particularly affect those
from seldom heard groups. Although less likely to pro-
vide continuous long-term input, involving community
or participant groups and close collaboration with vol-
untary organisations may offer better opportunities for
more diverse voices to contribute to the research
process. These approaches were predominantly used in
the HIV studies, which tended to involve people in a
wider variety of ways.
Perhaps the most novel finding of this study is the use
of participant involvement by three of the HIV trials (in-
cluding trials on prevention and treatment, and based in
the UK and Africa). This is distinct from usual PPI prac-
tice in clinical trials, where patient or community repre-
sentatives who are not taking part in the trial are chosen
for involvement roles. This approach is recommended as
Good Participatory Practice in biomedical HIV preven-
tion trials [26], but we are unaware of it being reported
in the formal literature elsewhere. None of the three
studies used participant involvement as their only form
of PPI, with researchers seeing it as complementing their
other PPI approaches to answer questions that people
who are not taking part in the trial cannot answer. We
see no obvious reasons why participant involvement
should not work equally well in other health-care research
areas and are currently exploring how we might adopt
them more widely at the MRC CTU at UCL. Participant
involvement may have particular advantages where the
intervention being tested is particularly novel (like
Box 1: Lessons learnt: the views of researchers and patient representatives
Who to involve:
● Enthusiasm for research was considered an essential characteristic for patient representatives. There was less agreement over what other skills or
attributes were essential.
● Patient representatives who had scientific backgrounds(in a variety of different areas of science) felt that helped them to adapt to the language
and processes of medical research
● Trial participants can provide unique insights because they are going through the trial. This may be very valuable.
● Some patient and community organisations can help to match interested people with research with researchers, based on their relevant skills
and experience and the focus of the research.
Providing support:
● Examples of support provided by researchers, that PPI representatives found to be useful include (but are not limited to):
▪ Taking time to explain things to patient representatives
▪ Helping patient representatives to prepare for meetings
▪ Organising visits to trial sites to see how the trial runs
▪ Providing a glossary of terms (including study-specific ones) that may be used.
▪ Remembering that patient representatives may be personally affected by discussions.
▪ Helping PPI representatives develop a better understanding of statistical concepts, especially at the analysis stage.
● Existing patient groups and community organisations can act as a vital bridge between researchers and patient and/or community
representatives
● Building on existing community structures (such as community groups, work places or traditional leadership groups) rather than trying to create
new ones can help to encourage community engagement (see MDP interview notes for more details)
● Having more than one PPI representative on a group or committee is important because:
▪ They can help to support each other
▪ It can help with the continuity of involvement, in particular where the study takes place over a prolonged period of time, or where there
may be high turnover of patient representatives
▪ It can help with diversity of involvement, in particular where there is considerable diversity in the population affected.
Types of involvement
● Integrating PPI at a cross-study or Unit level (e.g. Protocol Review Committee, or a panel of patient/community representatives to advise on
several studies in a disease area) may facilitate PPI in the development and early phases of a study.
● It can be helpful to involve people who are already well known and have strong links to, patient groups/the community, particularly for
involvement in more formal trial committees.
● Involving patients on data monitoring committees can be helpful, especially where side effects are an issue, as they can give a patient’s
perspective on the balance between risks and benefits.
● Using a mix of PPI models, i.e. having different types of involvement at different stages of a trial and with different groups and individuals, may
enhance the potential impacts of PPI.
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MDP301 and PROUD), so that other patients or commu-
nity members are unlikely to have experience of the issues
that come with the approach. It may also be advantageous
in disease areas where there are not already strong, estab-
lished patient groups from which to recruit patient
representatives.
There were no direct contradictions between the ac-
counts of researchers vs patient representatives. There
were some examples of an impact that were cited by one
interviewee and not the others for a single study, perhaps
because the other person interviewed may have been un-
aware of it. For example, the QUARTZ researcher said
that PPI had given them the confidence to keep going
with a trial that was struggling to recruit. The patient
representatives did not mention this as an example of
an impact, and subsequently told us he had been unaware
of it until we fed the results of the case studies back to
him.
Most of the literature on PPI to date has focused on
studies in high-income countries (particularly the UK).
Our case studies include three trials where all (DART and
MDP301) or a large proportion (BREATHER) of partici-
pants are from low-income countries (particularly sub-
Saharan African countries). The PPI models used in these
case studies all include community representation on the
steering committee (as did the other HIV case studies),
and participant meetings, with ongoing participant groups
for DART and MDP301. Only one of our studies based in
the UK (the PROUD HIV prevention study) involved par-
ticipants. Although there were similarities in the models
of PPI used in the three studies taking place in Africa,
there does not seem to be an obvious pattern in the areas
of impact described by interviewees, suggesting that the
area of impact is not solely related to the model of
involvement.
Half the examined studies combined a mix of different
PPI models, from long-term involvement in a formal
steering committee through to one-off work to produce a
video to promote the study. For example, in the PROUD
study, there was long-term involvement of community
representatives in the trial management group, trial steer-
ing committee and data monitoring committee, and in the
community engagement group. There was also one-off in-
volvement of participants in meetings to discuss specific
questions (e.g. how to improve recruitment, what the next
priority research question was, and how to interpret and
communicate the results). In the EPIC study, multiple ap-
proaches within a study were only identified in six out of
89 outline applications for HTA funding, so it seems that
this is not widespread [10]. In our study, the use of a var-
iety of different approaches to PPI within a single study
was seen only in the HIV studies and not in the cancer
studies. The reasons for this are not clear, but may in part
be due to the different cultures and traditions of PPI in
these two disease areas, and to the experience of the se-
nior researchers and teams involved in the studies. Where
studies used a mix of models of PPI, it is not possible to
attribute specific impacts to specific models. However, we
feel that certain models may be more or less likely to in-
fluence particular aspects of the research. For example,
the involvement of experienced patient representatives on
formal trial groups or committees may be more likely to
influence how studies are analysed than the one-off in-
volvement of participants who may have less knowledge
of clinical trials and who are less familiar with the process
and terminology. However, the one-off involvement of
trial participants may be best placed to react to and
resolve a specific problem that arises during a trial
(e.g. recruitment issues). Indeed, in studies of children
or young people, or very mobile populations, who may
be less able to contribute to ongoing formal committee
structures, short-term, more informal models may be the
only realistic option for active PPI. Although this is likely
to have resource implications, we feel that combining
different approaches may be cost-effective in the long term
by maximising the potential impacts of PPI on a study.
We recognise that different approaches to PPI will have
been adopted in other health-care areas and at other
clinical trials units. Broader sharing of these experiences,
their benefits and challenges may further benefit research
practice.
Conclusions
Our findings demonstrate that even within a single trials
unit, a range of models of PPI are being employed to
benefit clinical studies. Use of multiple models, possibly
at different stages of the research process, may maximise
the potential impacts of PPI in clinical research. Sharing
experiences of the different approaches being used, across
disease conditions and between clinical trials units, as well
as an exploration of the impact and benefits of these
approaches, is desirable. We recommend that researchers
familiarise themselves with a range of methods. In part-
nership with patient representatives, they should consider
which method(s) might be most appropriate, based on the
desired impact, the people they want to involve and the
time and resources available to support PPI.
Additional file
Additional file 1: Interview notes. This file contains notes from the
interviews conducted with both researchers and patient representatives
for the case studies. (PDF 423 kb)
Appendix: Interview topic guide
General
What was the study about? (One or two sentences in
plain English)
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Type of study (e.g. randomised, non-randomised,
epidemiology, meta-analysis)
For researchers
1. What was the aim of the involvement? What did
you hope to achieve by it?
2. Who did you involve (e.g. members of a patient
organisation or community group, members of the
public)? Why did you choose these people?
3. How did you find people to involve? Did you have
any problems finding people?
4. What methods did you use to involve people (e.g.
membership of a trial management group, trials
steering group, community advisory group)?
5. When were people involved (e.g. at what stages of
the research process)?
6. What activities did people undertake (e.g. reviewing
patient information sheets)?
7. How did you support people who were involved?
8. What did the involvement cost (time and money)?
9. What impact, if any, did the involvement have – on
the research, on the researchers and/or on the
patients/members of the public who got involved?
10.Any advice to other researchers thinking about PPI?
For people who get involved
1. Why did you agree to get involved in this project?
2. What did you hope to achieve? And did you
achieve it?
3. How were you involved?
4. Did you receive any support or training? If so, what
was this and was it helpful?
5. Do you feel your involvement had an impact – on
the project, on the researchers and/or on you?
6. Any advice to other researchers thinking about PPI?
7. Any advice to people who are asked to get involved
in research?
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